Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report

Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have demonstrated substantial effectiveness in individuals with advanced ALK-positive non-small cell lung cancer (NSCLC). However, the controversy over using ALK-TKIs for neoadjuvant therapy in ALK-positive NSCLC has not been fully exp...

Full description

Bibliographic Details
Main Authors:	Ruiqi Chen, Lilan Zhao, Juan Zhang, Lingwen Guo, Zhizhong Chen, Xiaojie Pan, Wenshu Chen
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	Heliyon
Subjects:	NSCLC Lorlatinib Neoadjuvant targeted therapy ALK pCR
Online Access:	http://www.sciencedirect.com/science/article/pii/S240584402308790X

Similar Items

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
by: Renaud Descourt, et al.
Published: (2022-03-01)

Recent Advances in the Management of Adverse Events Associated with Lorlatinib
by: Liao D, et al.
Published: (2023-09-01)

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
by: Tomoyo Taketa, et al.
Published: (2021-04-01)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
by: Gianluca Spitaleri, et al.
Published: (2023-05-01)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
by: Zhu VW, et al.
Published: (2020-01-01)

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
by: Marliese Alexander, B.Pharm(Hons), MPH, PhD, et al.
Published: (2023-04-01)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2021-07-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
by: Xiya Ma, et al.
Published: (2023-07-01)

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review
by: Viola W. Zhu, MD, PhD, et al.
Published: (2021-01-01)

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
by: Zhifeng Ye, et al.
Published: (2023-03-01)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
by: Rohit Thummalapalli, MD, et al.
Published: (2023-08-01)

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
by: Lee AT, et al.
Published: (2023-07-01)

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report
by: Annamaria Catino, et al.
Published: (2022-03-01)

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
by: Xu Feng, et al.
Published: (2021-06-01)

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib
by: Shubin W. Shahab, et al.
Published: (2023-02-01)

Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib
by: Stefano Testa, et al.
Published: (2021-06-01)

Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinib
by: Dan Liu, et al.
Published: (2024-03-01)

Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report
by: James A. Fletcher, M.B.B.S., et al.
Published: (2024-02-01)

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
by: Sergey V. Orlov, et al.
Published: (2021-08-01)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
by: Wenjie Liu, et al.
Published: (2024-02-01)

Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N
by: Na Li, et al.
Published: (2023-12-01)

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience
by: K. K. Laktionov, et al.
Published: (2021-12-01)

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
by: Sara Verdura, et al.
Published: (2022-12-01)

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
by: Takayuki Kobayashi, MD, et al.
Published: (2023-07-01)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
by: J. Guan, et al.
Published: (2016-09-01)

Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
by: Maximilian J. Hochmair, et al.
Published: (2020-11-01)

Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib
by: Xiaoqian Zhai, et al.
Published: (2023-03-01)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
by: Yun KM, et al.
Published: (2022-02-01)

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain
by: Wei Chen, et al.
Published: (2020-06-01)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
by: Sara Verdura, et al.
Published: (2022-09-01)

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
by: SiNi Li, et al.
Published: (2021-05-01)

Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT)
by: Shengyu Pu, et al.
Published: (2020-11-01)

Successful treatment of refractory brain metastases from ALK‐positive lung cancer with lorlatinib
by: Yoshiko Nakagawa, et al.
Published: (2022-05-01)

Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation  Treated with Ensartinib: A Case Report and Literature Review
by: Donglai LV, et al.
Published: (2023-01-01)

First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
by: Umair Majeed, MD, et al.
Published: (2023-07-01)

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
by: Balázs Jóri, et al.
Published: (2022-09-01)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
by: Hidetoshi Hayashi, MD, PhD, et al.
Published: (2023-04-01)

Current approaches to therapy of ALK-positive non-small cell lung cancer
by: К. К. Laktionov, et al.
Published: (2021-06-01)